Drug Trial Radar · NCT01077154
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4,509
Actual
Start
Jun 2, 2010
Primary completion
Aug 31, 2017
Study completion Mar 26, 2018
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Feb 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.
Conditions
- Breast Cancer
Interventions
PlaceboDrug
Administered subcutaneously for up to 5 years
DenosumabDrug
Administered subcutaneously for up to 5 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bone Metastasis-free Survival (BMFS)Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Locations
459 sites in 39 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Tucson, Arizona
Research Site
Jonesboro, Arkansas
Research Site
Alhambra, California
Research Site
Anaheim, California
Research Site
Beverly Hills, California
Research Site
Campbell, California
Research Site
Fresno, California
Research Site
Fullerton, California
Research Site
La Verne, California
Research Site
Lancaster, California
Research Site
Long Beach, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Redondo Beach, California
Research Site
Santa Barbara, California
Research Site
Santa Maria, California
Research Site
Torrance, California
Research Site
Denver, Colorado
Research Site
Grand Junction, Colorado
Research Site
New Haven, Connecticut
Research Site
Boynton Beach, Florida
Research Site
Coral Springs, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Melbourne, Florida
Research Site
Athens, Georgia
Research Site
Niles, Illinois
Research Site
Indianapolis, Indiana
Research Site
Cedar Rapids, Iowa
Research Site
Hutchinson, Kansas
Research Site
Wichita, Kansas
Research Site
Paducah, Kentucky
Research Site
Annapolis, Maryland
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Columbia, Maryland
Showing 40 of 459 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.